Submitted by sandy craine on Fri, 20/06/2014 - 11:30am
Jane de Lartigue, PhD Published Online: Monday, May 12, 2014
Renier J. Brentjens, MD, PhD, director of Cellular Therapeutics at Memorial Sloan Kettering (MSK) Cancer Center, focuses on the development of new therapies for patients with acute and chronic leukemias, in particular on novel immunotherapies such as chimeric antigen receptor (CAR) T cells. He is one of the founders of Juno Therapeutics, a start-up company launched in 2013 to expand cell-based immunotherapies, including CD19-targeted CAR T cells, into multiple cancer types. Brentjens, who is the director of Cellular Therapeutics at Memorial Sloan Kettering Cancer Center, discussed his research in this interview with OncologyLive.
Jane de Lartigue, PhD Published Online: Monday, May 12, 2014
Renier J. Brentjens, MD, PhD, director of Cellular Therapeutics at Memorial Sloan Kettering (MSK) Cancer Center, focuses on the development of new therapies for patients with acute and chronic leukemias, in particular on novel immunotherapies such as chimeric antigen receptor (CAR) T cells. He is one of the founders of Juno Therapeutics, a start-up company launched in 2013 to expand cell-based immunotherapies, including CD19-targeted CAR T cells, into multiple cancer types. Brentjens, who is the director of Cellular Therapeutics at Memorial Sloan Kettering Cancer Center, discussed his research in this interview with OncologyLive.
Submitted by sandy craine on Fri, 20/06/2014 - 11:23am
F Hayakawa1, K Sugimoto1,2, Y Harada2, N Hashimoto2, N Ohi2, S Kurahashi1 and T Naoe1
"Here, we demonstrated that a novel STAT3 inhibitor, OPB-31121, strongly inhibited not only STAT3 but also STAT5 phosphorylation. OPB-31121 did not inhibit activities of kinases including JFKs and SFKs and its exact mechanism of action is under investigation; however, it induced significant growth inhibition in a wide range of hematopoietic malignant cells. Investigation among various cell lines indicated that this compound was particularly effective against multiple myeloma and Burkitt lymphoma, and leukemia harboring BCR–ABL,
F Hayakawa1, K Sugimoto1,2, Y Harada2, N Hashimoto2, N Ohi2, S Kurahashi1 and T Naoe1
"Here, we demonstrated that a novel STAT3 inhibitor, OPB-31121, strongly inhibited not only STAT3 but also STAT5 phosphorylation. OPB-31121 did not inhibit activities of kinases including JFKs and SFKs and its exact mechanism of action is under investigation; however, it induced significant growth inhibition in a wide range of hematopoietic malignant cells. Investigation among various cell lines indicated that this compound was particularly effective against multiple myeloma and Burkitt lymphoma, and leukemia harboring BCR–ABL,
Submitted by sandy craine on Mon, 09/06/2014 - 1:49pm
Susan Branford1,*, David T. Yeung2, Wendy T. Parker1, Nicola D. Roberts1, Leanne Purins1, Jodi A. Braley1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Zoe Donaldson1, Mary Leong1, Linda Fletcher1, John F. Seymour3, Andrew P. Grigg4, David M. Ross5, and Timothy P. Hughes6
Susan Branford1,*, David T. Yeung2, Wendy T. Parker1, Nicola D. Roberts1, Leanne Purins1, Jodi A. Braley1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Zoe Donaldson1, Mary Leong1, Linda Fletcher1, John F. Seymour3, Andrew P. Grigg4, David M. Ross5, and Timothy P. Hughes6
Submitted by sandy craine on Thu, 15/05/2014 - 1:41pm
Carlo Gambacorti-Passerini,1
* Tim H. Brummendorf, 2,3 Dong-Wook Kim,4 Anna G. Turkina,5 Tamas Masszi,6
Carlo Gambacorti-Passerini,1
* Tim H. Brummendorf, 2,3 Dong-Wook Kim,4 Anna G. Turkina,5 Tamas Masszi,6
Submitted by sandy craine on Thu, 15/05/2014 - 12:46pm
L. Legros, J. Guilhot, S. Huault, F.X. Mahon, C. Preudhomme, F. Guilhot, A.O. Hueber, from the French CML Group (FI-LMC)
L. Legros, J. Guilhot, S. Huault, F.X. Mahon, C. Preudhomme, F. Guilhot, A.O. Hueber, from the French CML Group (FI-LMC)
Submitted by sandy craine on Thu, 08/05/2014 - 2:38pm
David M. Ross1,2,3,4, Susan Branford5, John F. Seymour2,6, Anthony P. Schwarer2,7, Christopher Arthur2,8, David T. Yeung1,2,3, Phuong Dang1, Jarrad M. Goyne1, Cassandra Slader9, Robin J. Filshie2,10, Anthony K. Mills2,11, Junia V. Melo1,3, Deborah L. White1,2,3, Andrew P. Grigg2,12, and Timothy P. Hughes1,2,3
David M. Ross1,2,3,4, Susan Branford5, John F. Seymour2,6, Anthony P. Schwarer2,7, Christopher Arthur2,8, David T. Yeung1,2,3, Phuong Dang1, Jarrad M. Goyne1, Cassandra Slader9, Robin J. Filshie2,10, Anthony K. Mills2,11, Junia V. Melo1,3, Deborah L. White1,2,3, Andrew P. Grigg2,12, and Timothy P. Hughes1,2,3
Submitted by sandy craine on Fri, 04/04/2014 - 12:45pm
Michael Lauseker1,Joerg Hasford1, Markus Pfirrmann1, and Rüdiger Hehlmann2
Key points
* Chronic myeloid leukemia patients enjoyed superior survival chances when treated in teaching hospitals.
Michael Lauseker1,Joerg Hasford1, Markus Pfirrmann1, and Rüdiger Hehlmann2
Key points
* Chronic myeloid leukemia patients enjoyed superior survival chances when treated in teaching hospitals.
Submitted by sandy craine on Wed, 12/03/2014 - 3:39pm
Neil P. Shah1,*, François Guilhot2, Jorge E. Cortes3, Charles A. Schiffer4, Philipp le Coutre5, Tim H. Brümmendorf6, Hagop M. Kantarjian3, Andreas Hochhaus7, Philippe Rousselot8, Hesham Mohamed9, Diane Healey10, Michael Cunningham10, and Giuseppe Saglio11
Neil P. Shah1,*, François Guilhot2, Jorge E. Cortes3, Charles A. Schiffer4, Philipp le Coutre5, Tim H. Brümmendorf6, Hagop M. Kantarjian3, Andreas Hochhaus7, Philippe Rousselot8, Hesham Mohamed9, Diane Healey10, Michael Cunningham10, and Giuseppe Saglio11
Submitted by sandy craine on Tue, 04/03/2014 - 12:54pm
*Clinical Care Options: Oncology.
*Clinical Care Options: Oncology.
Submitted by sandy craine on Tue, 11/02/2014 - 12:20pm
London, UK, January 09, 2014 --
The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer’s BOSULIF® (bosutinib).
London, UK, January 09, 2014 --
The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer’s BOSULIF® (bosutinib).
Pages
